Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%

Infliximab vs adalimumab

Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.54]
1 study · 73 participants
Very low

Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo

Serious adverse events up to week 12 · Patients with active Crohn's disease

Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.82 [0.29, 2.3]
1 study · 129 participants
Low

Two infusions of natalizumab (6 mg/kg) vs placebo

Serious adverse events up to week 12 · Patients with active Crohn's disease

Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 1.06 [0.38, 2.95]
1 study · 114 participants
Low

Three infusions of natalizumab (300 mg) vs placebo

Serious adverse events up to week 12 · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.76 [0.37, 1.56]
2 studies · 1414 participants
Low

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.52 [0.03, 7.98]
1 study · 79 participants
Low

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Serious adverse events up to week 12 · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.93 [0.34, 2.49]
1 study · 131 participants
Low